10 Jun 2024 --- Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST — fecal microbiota spores, live-brpk (a novel protein kinase) — capsules from Seres Therapeutics. The companies have agreed to a non-binding memorandum of understanding. VOWST is the first and only orally administered microbiota-based therapeutic approved by the US Food and Drug Administration (FDA) to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI.
